Clinical trials: Rituximab, completed
Non-Hodgkins Lymphoma, B-cell Lymphoma
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
- Conditions
- Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma
- Trial name
- NCT01647971
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- TG Therapeutics, Inc.
Non-Hodgkin's Lymphoma
Treatment for Subjects With Non-Hodgkin's Lymphoma
This multicenter, open-label, randomized, parallel study was designed to evaluate whether a single fixed-dose subcutaneous (SC) administration of pegfilgrastim or daily administration of Filgrastim for absolute neutrophil count…
- Trial name
- NCT00117897
- Testing
- pegfilgrastim, Filgrastim
- Sponsor
- Amgen
Chronic Lymphocytic Leukaemia
Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders
The purpose of this study is collect and evaluate the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic…
- Trial name
- NCT01832597
- Where
- 3 sites in Italy
- Volunteers
- 109 people
- Sponsor
- Gruppo Italiano Studio Linfomi
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098774
- Testing
- filgrastim, rituximab, cytarabine
- Where
- 30 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Hodgkin's Lymphoma
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera.
- Trial name
- NCT01153971
- Testing
- rituximab
- Where
- 15 sites in Italy
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Follicular Lymphoma
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma
Patients with stage I and II low grade follicular lymphoma are randomised between standard therapy (involved field radiotherapy) and investigational therapy (involved field radiotherapy and chemotherapy plus rituximab).
- Trial name
- NCT00115700
- Testing
- Cyclophosphamide, Radiotherapy, Vincristine
- Where
- 21 sites in Australia, Canada and 1 more
- Volunteers
- 150 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
The goal of the study is to identify a dose and schedule of CC-486 that can be safely administered with R-CHOP. To evaluate the safety and maximum tolerated dose (MTD) or the maximal administered dose (MAD) of CC-486 in…
- Trial name
- NCT02343536
- Testing
- Oral Azacitidine, Rituximab, cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 59 people
- Sponsor
- Celgene
Rheumatoid Arthritis, Interstitial Pneumonia
Rituximab in Rheumatoid Arthritis Lung Disease
This study will examine the course of patients with progressive rheumatoid arthritis associated interstitial lung disease (RA-ILD) treated with rituximab for safety and progression-free survival at 48 weeks.
- Trial name
- NCT00578565
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Eric Matteson
Microscopic Polyangiitis (MPA)
Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis
The purpose of the study is to determine wether a rituximab-based treatment compared to standard therapy (glucocorticoid alone) in patients with microscopic polyangiitis without any bad prognosis marker increases the remission…
- Trial name
- RITUXGOPRO (NCT03920722)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Obsessive-Compulsive Disorder, Treatment Resistant Disorders
Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)
This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant obsessive-compulsive disorder in an open trial.
- Trial name
- NCT03983031
- Testing
- Rituximab
- Where
- 2 sites in Sweden
- Volunteers
- 11 people
- Sponsor
- Region Örebro County
Chronic Lymphocytic Leukemia (CLL)
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell…
- Trial name
- NCT01466153
- Testing
- Rituximab, Bendamustine, MEDI-551
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 183 people
- Sponsor
- MedImmune LLC
Lymphoma
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00770224
- Testing
- rituximab, tositumomab, cyclophosphamide
- Where
- 114 sites in United States
- Volunteers
- 87 people
- Sponsor
- SWOG Cancer Research Network
B-cell Lymphoma, Chronic Lymphocytic Leukaemia
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
The purpose of this trial is to identify the tolerable dose of BI-1206 (both alone and in combination) for patients with B-cell lymphoma and leukaemia and further evaluate BI-1206 alone and in combination with an anti-CD20…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukaemia, Waldenström Macroglobulinemia
- Trial name
- NCT02933320
- Testing
- BI-1206 single agent dose escalation phase, Combination of BI-1206 with rituximab escalation phase, BI-1206 single agent expansion phase
- Where
- 5 sites in United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cancer Research UK
Lymphoma, B-Cell, Follicular Lymphoma
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
This is an open-label (doctors and patients know which drug will be given), single center, phase 1/2 clinical trial. The primary objective is to determine whether VR-CHOP provides benefit to patients with previously untreated…
- Trial name
- NCT00634179
- Testing
- Bortezomib, Rituximab, Doxorubicin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Emory University
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with relapsed/refractory Diffuse Large B-cell Lymphoma…
- Trial name
- NCT02142049
- Testing
- Ibrutinib, DA-EPOCH-R, Lenalidomide
- Where
- 10 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pharmacyclics LLC.
Blood Stem Cell Transplant Failure, Leukemia
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
The goal of this clinical research study is to learn about the safety of giving a stem cell transplant from a tissue-mismatched donor, followed by cyclophosphamide, to patients with certain types of blood disorders or blood…
- Conditions
- Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies
- Trial name
- NCT01010217
- Testing
- Cyclophosphamide, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with…
- Trial name
- NCT01855750
- Testing
- Ibrutinib, Rituximab, Cyclophosphamide
- Where
- 201 sites in United States, Argentina and 25 more
- Volunteers
- 838 people
- Sponsor
- Janssen Research & Development, LLC
Pemphigus Vulgaris
A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
This is a Phase III, randomized, double-blind, double-dummy, active-comparator, parallel-arm, multicenter study to evaluate the efficacy and safety of rituximab compared with MMF in participants with moderate-to-severely active…
- Trial name
- NCT02383589
- Testing
- Mycophenolate Mofetil, Rituximab
- Where
- 68 sites in United States, Argentina and 10 more
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Nephrotic Syndrome
Rituximab for Idiopathic Nephrotic Syndrome
Open-label, randomized, controlled trial due to value whether the monoclonal antibody rituximab is non-inferior to steroids in maintaining remission in juvenile forms of SDNS.
- Trial name
- NCT04494438
- Testing
- Rituximab
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Istituto Giannina Gaslini
Neuromyelitis Optica Spectrum Disorder
Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
The purpose of this study is to compare annual relapse rate, expanded disability status scale, and side effects of azathioprine and rituximab in patients with neuromyelitis optica spectrum disorder during a one year follow up…
- Trial name
- NCT03002038
- Testing
- Azathioprine, Rituximab
- Where
- Iran
- Volunteers
- 86 people
- Sponsor
- Isfahan University of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.